Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

Abstract

Background Real-world clinical data to support the use of casirivimab–imdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimab–imdevimab treatment of mild to moderate COVID-19. Methods A retrospective cohort of 696 patients who received casirivimab–imdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion. Findings The median age of the antibody-treated cohort was 63 years (interquartile range, 52–71); 45·5% were ≥65 years old; 51.4% were female. High-risk characteristics were hypertension (52.4%), body mass index ≥35 (31.0%), diabetes mellitus (24.6%), chronic lung disease (22.1%), chronic renal disease (11.4%), congestive heart failure (6.6%), and compromised immune function (6.7%). Compared to the propensity-matched untreated control, patients who received casirivimab–imdevimab had significantly lower all-cause hospitalization rates at day 14 (1.3% vs 3.3%; Absolute Difference: 2.0%; 95% confidence interval (CI): 0.5–3.7%), day 21 (1.3% vs 4.2%; Absolute Difference: 2.9%; 95% CI: 1.2–4.7%), and day 28 (1.6% vs 4.8%; Absolute Difference: 3.2%; 95% CI: 1.4–5.1%). Rates of intensive care unit admission and mortality at days 14, 21 and 28 were similarly low for antibody-treated and untreated groups. Interpretation Among high-risk patients with mild to moderate COVID-19, casirivimab–imdevimab treatment was associated with a significantly lower rate of hospitalization. Funding Mayo Clinic.

The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India

“…This result resembled the findings put forward by Raymund et al where, out of 708 patients on Casirivimab and Imdevimab, only an individual passed away. 4 …”

“…These agents block the virus's entry into the host cells by specifically attaching to the receptor-binding domain of SARS-CoV-2's, spike glycoprotein. 4 The combination is indicated for high-risk individuals who has Chronic Liver, Kidney (estimated glomerular filtration rate <60ml/min), and, Respiratory Diseases, immunocompromising conditions, Cardiovascular Diseases, Diabetes Mellitus (HbA1c > 10%), Malignancies, and those with body mass index ≥35Kg/m2, age ≥65 of years and other indications that deemed fit by the institutional medical board. The approved dose for those above 12 years of age and weighing at least 40 kg is 600mg for each of the drugs.…”

The impact of COVID-19 in children post hematopoietic stem cell transplantation: Experience from a pediatric transplant unit in India

“…Since viremia from SARS-CoV-2 is usually profound, at least in children beyond 12 years of age, giving REGEN-COV (Casirivimab and Imdevimab) that bind to non-overlapping epitopes of the spike protein receptor-binding domain (RBD) of SARS-CoV-2 and reducing viremia could be beneficial [ 16 ]. Especially in children less than six months post HSCT and those on immunosuppressants where the immune system is not at its adequacy, this monoclonal antibody cocktail can help reduce viremia and the associated cytokine-mediated morbidity.…”

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy

“…In outpatients with mild to moderate SARS-CoV-2, a placebo-controlled randomized trial looked at different dosages of casirivimab plus imdevimab ( Razonable et al., 2021 ). FDA simplified the EUA for casirivimab plus imdevimab, reducing the approved dose for single intravenous infusion from casirivimab 1200 mg plus imdevimab 1200 mg to casirivimab 600 mg plus imdevimab 600 mg (NCT04425629) ( Deeks, 2021 ; Razonable et al, 2021 ). Participants included were 18 years of age or older, tested positive for SARS-CoV-2, and had at least one risk factor for developing severe SARS-CoV-2.…”